Published in Ann Intern Med on June 01, 2004
Fondaparinux as Monotherapy for DVT and/or Pulmonary Embolism | NCT00413504
Low molecular weight heparin inhibits plasma thrombin generation via direct targeting of factor IXa: contribution of the serpin-independent mechanism. J Thromb Haemost (2012) 2.09
Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study. J Thromb Thrombolysis (2009) 1.71
Venous thromboembolism. BMJ (2006) 1.52
Diagnosis and treatment of deep-vein thrombosis. CMAJ (2006) 1.44
Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood (2005) 1.43
Patient outcomes after deep vein thrombosis and pulmonary embolism: the Worcester Venous Thromboembolism Study. Arch Intern Med (2008) 1.36
Computationally derived points of fragility of a human cascade are consistent with current therapeutic strategies. PLoS Comput Biol (2007) 1.33
New anticoagulants: how to deal with treatment failure and bleeding complications. Br J Clin Pharmacol (2011) 1.11
Venous thromboembolism and bleeding in a community setting. The Worcester Venous Thromboembolism Study. Thromb Haemost (2009) 1.09
Use of anticoagulants in elderly patients: practical recommendations. Clin Interv Aging (2009) 1.04
Venous thromboembolism in the elderly. A community-based perspective. Thromb Haemost (2008) 0.99
Anticoagulation by factor Xa inhibitors. J Thromb Haemost (2010) 0.99
Anticoagulants: A Review of the Pharmacology, Dosing, and Complications. Curr Emerg Hosp Med Rep (2013) 0.95
Pre-operative thrombotic complications of neoadjuvant chemotherapy for breast cancer: Implications for immediate breast reconstruction. Ann Med Surg (Lond) (2014) 0.90
Venous thromboembolism: classification, risk factors, diagnosis, and management. ISRN Hematol (2011) 0.89
Treatment and secondary prevention of venous thromboembolism in cancer. Br J Cancer (2010) 0.88
New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin. Br J Pharmacol (2005) 0.86
Comparative assessment of low-molecular-weight heparins in cancer from the perspective of patient outcomes and survival. Patient Relat Outcome Meas (2011) 0.85
Fondaparinux-associated heparin-induced thrombocytopenia. Proc (Bayl Univ Med Cent) (2012) 0.85
Diagnosis and treatment of deep-vein thrombosis and approach to venous thromboembolism in obstetrics and gynecology. J Turk Ger Gynecol Assoc (2011) 0.83
Inferior vena cava filters in cancer patients: to filter or not to filter. Ther Clin Risk Manag (2011) 0.83
Anticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism: The Present State of the Art. Front Cardiovasc Med (2015) 0.82
Venous thromboembolism prophylaxis for hospitalized medical patients, current status and strategies to improve. Ann Thorac Med (2010) 0.80
Differentiation of parenteral anticoagulants in the prevention and treatment of venous thromboembolism. Thromb J (2011) 0.80
Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance. Ther Adv Drug Saf (2012) 0.80
Dealing with thrombocytopenia during anticoagulation with heparins for active venous thromboembolism: a play-it-safe practical approach. Ther Clin Risk Manag (2011) 0.79
Recent advances in the management of venous thromboembolism. Korean J Hematol (2010) 0.78
Increased major bleeding risk in patients with kidney dysfunction receiving enoxaparin: a meta-analysis. Eur J Clin Pharmacol (2011) 0.78
Rivaroxaban and other non-vitamin K antagonist oral anticoagulants in the emergency treatment of thromboembolism. Int J Emerg Med (2013) 0.78
Prevention and treatment of venous thromboembolism with low-molecular-weight heparins: Clinical implications of the recent European guidelines. Thromb J (2008) 0.78
Clinical use of the low-molecular-weight heparins in cancer patients: focus on the improved patient outcomes. Thrombosis (2011) 0.77
Diagnosis and management of iliofemoral deep vein thrombosis: clinical practice guideline. CMAJ (2015) 0.77
Deep vein thrombosis: how long will it remain? J Anesth (2010) 0.77
Prevention and treatment of venous thromboembolism in the elderly patient. Clin Interv Aging (2007) 0.77
Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism. J Thromb Thrombolysis (2016) 0.77
Deep Venous Thrombosis: An Interventionalist's Approach. Ochsner J (2014) 0.77
Diagnosis and treatment of pulmonary embolism: a multidisciplinary approach. Multidiscip Respir Med (2013) 0.77
Deep vein thrombosis: current status and nanotechnology advances. Biotechnol Adv (2012) 0.77
Antiplatelet medications and evolving antithrombotic medication. Skeletal Radiol (2013) 0.76
Inhibitors of propagation of coagulation: factors V and X. Br J Clin Pharmacol (2011) 0.76
Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin. Cancer Lett (2014) 0.76
Toward the simplification of antithrombotic treatment of venous thromboembolism. Ann Intern Med (2004) 0.75
Summaries for patients. Fondaparinux or enoxaparin for deep venous thrombosis? Ann Intern Med (2004) 0.75
Successful management of acute thromboembolic disease complicated with heparin induced thrombocytopenia type II (HIT II): a case series. Thromb J (2008) 0.75
Fondaparinux vs warfarin for the treatment of unsuspected pulmonary embolism in cancer patients. Drug Des Devel Ther (2016) 0.75
Fondaparinux in the management of patients with ST-elevation acute myocardial infarction. Vasc Health Risk Manag (2006) 0.75
Reduction of the incidence of development of venous thromboembolism by ultrasound-guided femoral nerve block in total knee arthroplasty. Korean J Anesthesiol (2011) 0.75
Correspondence (letter to the editor): Severe Renal Insufficiency. Dtsch Arztebl Int (2008) 0.75
The treatment of deep vein thrombosis in the pelvis and leg. Dtsch Arztebl Int (2008) 0.75
Fondaparinux was as effective as (noninferior to) enoxaparin in acute symptomatic deep venous thrombosis. ACP J Club (2004) 0.75
New anticoagulants for the prevention and treatment of venous thromboembolism. Vasc Health Risk Manag (2005) 0.75
Efficacy and safety of venous thromboembolism prophylaxis with fondaparinux or low molecular weight heparin in a large cohort of consecutive patients undergoing major orthopaedic surgery - findings from the ORTHO-TEP registry. Br J Clin Pharmacol (2012) 0.75
Role of factor xa inhibitors in cancer-associated thrombosis: any new data? Adv Hematol (2011) 0.75
New anticoagulants for the treatment of venous thromboembolism. J Bras Pneumol (2016) 0.75
[Thrombosis prophylaxis in geriatric patients]. Z Gerontol Geriatr (2012) 0.75
Thromboembolic disease in cancer patients. Support Care Cancer (2013) 0.75
[Diagnostic assessment of perioperative thromboembolism]. Wien Med Wochenschr (2009) 0.75
Initial anticoagulation in patients with pulmonary embolism: thrombolysis, unfractionated heparin, LMWH, fondaparinux, or DOACs? Br J Clin Pharmacol (2017) 0.75
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med (2012) 11.86
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med (2003) 11.00
Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med (2004) 10.02
Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med (2010) 9.92
Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.55
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med (2013) 7.76
The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol (2003) 7.54
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet (2009) 6.83
D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med (2006) 6.62
A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med (2003) 6.57
Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med (2012) 6.42
Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 5.96
Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA (2006) 5.69
Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med (2004) 5.68
Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med (2010) 5.59
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet (2007) 5.41
American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol (2007) 5.36
Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force. Chest (2006) 4.77
Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. JAMA (2006) 4.75
Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J (2005) 4.46
Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. Ann Intern Med (2009) 4.27
Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med (2003) 3.94
Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann Intern Med (2004) 3.74
Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med (2007) 3.64
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood (2002) 3.59
Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med (2002) 3.51
Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol (2005) 3.42
An association between atherosclerosis and venous thrombosis. N Engl J Med (2003) 3.39
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet (2010) 3.29
Left bundle-branch block induced by transcatheter aortic valve implantation increases risk of death. Circulation (2012) 2.95
Nebulized 5% or 3% hypertonic or 0.9% saline for treating acute bronchiolitis in infants. J Pediatr (2010) 2.91
Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med (2009) 2.90
Cost-effectiveness of Mohs Micrographic Surgery vs Surgical Excision for Basal Cell Carcinoma of the Face. Arch Dermatol (2006) 2.84
Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review. J Hypertens (2004) 2.71
Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol (2010) 2.59
Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J Rheumatol (2009) 2.58
Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 2.50
Safe exclusion of pulmonary embolism using the Wells rule and qualitative D-dimer testing in primary care: prospective cohort study. BMJ (2012) 2.38
Comparing the diagnostic performance of 2 clinical decision rules to rule out deep vein thrombosis in primary care patients. Ann Fam Med (2011) 2.34
The incidence of recurrent venous thromboembolism after treatment with vitamin K antagonists in relation to time since first event: a meta-analysis. Arch Intern Med (2003) 2.33
Diagnostic strategies for excluding pulmonary embolism in clinical outcome studies. A systematic review. Ann Intern Med (2003) 2.33
The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol (2005) 2.31
Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology (2005) 2.30
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty (2008) 2.30
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J (2013) 2.21
Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery? Anesthesiology (2006) 2.18
Safely ruling out deep venous thrombosis in primary care. Ann Intern Med (2009) 2.16
Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet (2011) 2.09
Quality of life in the Canadian Implantable Defibrillator Study (CIDS). Am Heart J (2002) 2.09
Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis. Intern Emerg Med (2009) 2.03
The association of direct thrombin inhibitor anticoagulants with cardiac thromboses. Chest (2015) 1.97
Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med (2006) 1.88
Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA (2005) 1.87
Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial. Circulation (2006) 1.86
Sex-based differences in the effect of intra-arterial treatment of stroke: analysis of the PROACT-2 study. Stroke (2006) 1.86
Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J (2006) 1.84
Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med (2007) 1.84
Single-detector helical computed tomography as the primary diagnostic test in suspected pulmonary embolism: a multicenter clinical management study of 510 patients. Ann Intern Med (2003) 1.83
A meta-analysis on the efficacy of preoperative biliary drainage for tumors causing obstructive jaundice. Ann Surg (2002) 1.79
An evaluation of D-dimer in the diagnosis of pulmonary embolism: a randomized trial. Ann Intern Med (2006) 1.78
Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest (2010) 1.67
Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: the Euro Heart Survey. Europace (2012) 1.67